Trial Profile
A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2012
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Kaposi's sarcoma
- Focus Biomarker; Therapeutic Use
- 11 Aug 2011 New trial record